IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO. (June 2017) - Wang, M.L.